Scientists have developed a way to engineer immune cells that specifically target tumors. The application of engineering cells first appeared in the 1980s, but the concept has significantly progressed over the last few decades. This approach of engineering a patient’s cells as a form of therapy allow the immune system to specifically target the tumor and limit off-target affects.
Chimeric antigen receptor (CAR) T cells is an immunotherapy that takes patient T cells and edits them to target the tumor. The cells are then reinfused to accurately and effectively eliminate tumor growth. Immunotherapy is a general classification of cancer treatments that refers to the redirection of the immune system toward a disease or infection. T cells are responsible for the identification and elimination of infected cells and other diseases. Therefore, they are the optimal cell to engineer for robust and durable antitumor immunity. While scientists are working to engineer other cell types, CAR T cell therapy have been shown to have improved efficacy in multiple types of blood or hematological malignancies.
CAR T cell therapy in solid tumors is less effective. Unfortunately, the environment around the tumor has a complex network of various cell types combined with proteins and other molecules that inhibit CAR T cell efficacy. As a result, these CAR T cells cannot function and contribute to tumor progression. Scientists are currently working to improve CAR T cell therapy and develop stronger anti-cancer treatments.








